BaigentCBlackwellLEmbersonJ. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
2.
BaigentCKeechAKearneyPM. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–1278.
3.
CannonCPSteinbergBAMurphySAMegaJLBraunwaldE. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48(3):438–445.
4.
BarkasFMilionisHKostapanosMSMikhailidisDPElisafMLiberopoulosE. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic. Curr Med Res Opin. 2015;31(2):221–228.
5.
KotsevaKWoodDDe BacquerD. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries[published online February 16, 2015]. Eur J Prev Cardiol. 2015.
6.
BarkasFLiberopoulosENKostapanosMSLiamisGTziallasDElisafM. Lipid target achievement among patients with very high and high cardiovascular risk in a lipid clinic. Angiology. 2015;66(4):346–353.
7.
ReinerZCatapanoALDe BackerG. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769–1818.
8.
RydenLGrantPJAnkerSD. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary. Diab Vasc Dis Res. 2014;11(3):133–173.
9.
LeiterLALundmanPda SilvaPM. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med. 2011;28(11):1343–1351.
10.
KostapanosMSElisafMSMikhailidisDP. Ezetimibe - a new approach in hypercholesterolemia management. Pharmacol Rep. 2012;64(4):997–998.
11.
KostapanosMSMikhailidisDPElisafMS. Adding ezetimibe to statin treatment: is LDL-C lowering the only benefit?Future Cardiol. 2012;8(6):813–817.
12.
MikhailidisDPSibbringGCBallantyneCMDaviesGMCatapanoAL. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin. 2007;23(8):2009–2026.
13.
SudhopTLutjohannDKodalA. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106(15):1943–1948.
14.
MorroneDWeintraubWSTothPP. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223(2):251–261.
15.
KalogirouMTsimihodimosVGaziI. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin. 2007;23(5):1169–1176.
16.
CannonCPBlazingMAGiuglianoRP. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–2397.
17.
JarchoJAKeaneyJFJr. Proof that lower is better--LDL cholesterol and IMPROVE-IT. N Engl J Med. 2015;372(25):2448–2450.
18.
IpCKJinDMGaoJJ. Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials. Int J Cardiol. 2015;191:138–148.
19.
FarnierM. Ezetimibe/statin combination therapy to treat patients with type 2 diabetes. Atheroscler Suppl. 2015;17:2–8.
20.
LuoLYuanXHuangW. Safety of coadministration of ezetimibe and statins in patients with hypercholesterolaemia: a meta-analysis. Intern Med J. 2015;45(5):546–557.
21.
StitzielNOWonHHMorrisonAC. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med. 2014;371(22):2072–2082.
22.
FerenceBAMajeedFPenumetchaRFlackJMBrookRD. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial mendelian randomization study. J Am Coll Cardiol. 2015;65(15):1552–1561.
23.
LauridsenBKStenderSFrikke-SchmidtRNordestgaardBGTybjaerg-HansenA. Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease. Eur Heart J. 2015;36(25):1601–1608.
24.
BaysHEChenETomassiniJEMcPetersGPolisABTriscariJ. Fixed-dose combination ezetimibe+atorvastatin lowers LDL-C equivalent to co-administered components in randomized trials: use of a dose-response model. Fundam Clin Pharmacol. 2015;29(2):209–218.
25.
FlorentinMElisafMS. Simvastatin interactions with other drugs. Expert Opin Drug Saf. 2012;11(3):439–444.
26.
AdachiHNakanoHYamamotoK. Ezetimibe ameliorates atherogenic lipids profiles, insulin resistance and hepatocyte growth factor in obese patients with hypercholesterolemia. Lipids Health Dis. 2015;14(1):1.
27.
SaitoIAzumaKKakikawaTOshimaNHansonMETershakovecAM. A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia. Lipids Health Dis. 2015;14:40.
28.
Ohbu-MurayamaKAdachiHHiraiY. Ezetimibe combined with standard diet and exercise therapy improves insulin resistance and atherosclerotic markers in patients with metabolic syndrome. J Diabetes Investig. 2015;6(3):325–333.
29.
ChangEKimLChoiJM. Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition. Metabolism. 2015;64(5):633–641.
30.
MoutzouriELiberopoulosENTellisCCMilionisHJTselepisADElisafMS. Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia. Atherosclerosis. 2013;231(1):8–14.
31.
MoutzouriETellisCCRousouliK. Effect of simvastatin or its combination with ezetimibe on Toll-like receptor expression and lipopolysaccharide - induced cytokine production in monocytes of hypercholesterolemic patients. Atherosclerosis. 2012;225(2):381–387.
32.
KostapanosMSSpyrouATTellisCC. Ezetimibe treatment lowers indicators of oxidative stress in hypercholesterolemic subjects with high oxidative stress. Lipids. 2011;46(4):341–348.
33.
KalogirouMTsimihodimosVElisafM. Pleiotropic effects of ezetimibe: do they really exist?Eur J Pharmacol. 2010;633(1-3):62–70.
34.
SaougosVGTambakiAPKalogirouM. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol. 2007;27(10):2236–2243.
35.
NakouESFilippatosTDKiortsisDN. The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opin Pharmacother. 2008;9(18):3151–3158.
36.
NakouESFilippatosTDAgouridisAPKostaraCBairaktariETElisafMS. The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients. Lipids. 2010;45(5):445–450.
37.
KuboMMiyoshiTKimuraT. Add-on ezetimibe reduces small dense low-density lipoprotein cholesterol levels without affecting absorption of eicosapentaenoic acid in patients with coronary artery disease: a pilot study. Am J Cardiovasc Drugs. 2014;14(5):387–392.
38.
FlorentinMLiberopoulosENMoutzouriERizosCVTselepisADElisafMS. The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Curr Med Res Opin. 2011;27(3):685–692.
39.
NakouESFilippatosTDGeorgoulaM. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin. 2008;24(7):1919–1929.
40.
KostapanosMSElisafMSMikhailidisDP. Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipidemia. J Cardiovasc Pharmacol Ther. 2012;17(4):427.
41.
TakeshitaYTakamuraTHondaM. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia. 2014;57(5):878–890.
42.
FilippatosTDElisafMS. Role of ezetimibe in non-alcoholic fatty liver disease. World J Hepatol. 2011;3(10):265–267.
